AstraZeneca Bets On UK Listed Firm For Lung Diseases

• Drug Discovery company C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca plc (NASDAQ: AZN) worth up to $402 million for its NRF2 Activator program.

• C4X Discovery is listed on the London Stock exchange, and the deal is the third significant deal with a major pharmaceutical company.

• AstraZeneca will develop and commercialize an oral therapy for inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).

• Related: FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids.

• Under the terms of the agreement, C4XD will receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront.

• In addition, C4XD is eligible to receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialization.

• Price Action: AZN shares are up 0.05% at $66.21 premarket on the last check Monday.

See more from Benzinga

• European Official Says COVID-19 Booster Uptake Disappointing In The Region

• Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says

• Bill Clinton Takes A Shot At Donald Trump: Here's What He Said - Paramount Global (NASDAQ:PARA)

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.